Actinogen Limited (ASX:ACW)
CEO Dr Bill Ketelbey presents at the ASX Investor Series in Perth.
The biotechnology group’s presentation is titled, “Developing Xanamem™ for Alzheimer’s Dementia”.
Dr Ketelbey describes Alzheimer’s as ‘one of the most significant health challenges of our time’.
The presentation looks at the company’s product Xanamem™, in development as a treatment for Alzheimer's disease and prodromal Alzheimer's/mild cognitive impairment.
Dr Ketelbey discusses Xanamem™’s pre-clinical data, development milestones, clinical advisory board and pipeline.
The presentation concludes with a summary of Actinogen’s financial profile, investment highlights and board and management.